Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. The company's clinical stage programs also include TRX518, a monoclonal antibody, which is in clinical trial targeting the glucocorticoid-induced tumor necrosis factor-related receptor in patients with solid tumors. It has collaboration agreement with Merck KGaA and Pfizer Inc. to evaluate the company's TRX518, a GITR agonist, in combination with avelumab, a human anti-PD-L1 IgG1 monoclonal antibody, and chemotherapy. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was founded in 2011 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
Previous Symbol
CUSIPN/A
Phone617-714-0360
Debt
Debt-to-Equity RatioN/A
Current Ratio4.03
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-0.87
Forward P/E Ratio-1.21
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$0.90 per share
Price / Book3.19
Profitability
EPS (Most Recent Fiscal Year)($3.31)
Net Income$-29,720,000.00
Net MarginsN/A
Return on Equity-239.16%
Return on Assets-85.07%
Miscellaneous
Employees22
Outstanding Shares14,700,000
Market Cap$47.05 million
OptionableNot Optionable
Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions
What is Leap Therapeutics' stock symbol?
Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."
How were Leap Therapeutics' earnings last quarter?
Leap Therapeutics Inc (NASDAQ:LPTX) issued its quarterly earnings results on Thursday, November, 15th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.02. View Leap Therapeutics' Earnings History.
When is Leap Therapeutics' next earnings date?
What price target have analysts set for LPTX?
1 analysts have issued 12-month target prices for Leap Therapeutics' shares. Their predictions range from $13.00 to $13.00. On average, they anticipate Leap Therapeutics' share price to reach $13.00 in the next year. This suggests a possible upside of 361.0% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.
What is the consensus analysts' recommendation for Leap Therapeutics?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.
What are Wall Street analysts saying about Leap Therapeutics stock?
Here are some recent quotes from research analysts about Leap Therapeutics stock:
- 1. According to Zacks Investment Research, "Leap Therapeutics, Inc. is a biopharmaceutical company. It develops novel therapeutics for the treatment of cancer. Leap Therapeutics, Inc. is based in Cambridge, United States. " (10/6/2018)
- 2. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] Initial DKN-01 Results Show Promise; Anti- GITR Combines Well With Chemo; Reiterate Buy Preclinical and clinical results highlights the effects of DKN-01 on the immune system. On April 16, Leap presented new results at the 2018 American Association for Cancer Research (AACR) Annual Conference that highlight the immunomodulatory effect of DKN-01 in preclinical tumor models. According to the latest results, DKN-01 is able to significantly alter the makeup of the tumor microenvironment (Exhibit 1), attract immune cells by inducing Cxcl10 expression (Exhibit 2), and improve the efficacy of PD-1 checkpoint inhibition (Exhibit 3)." (4/12/2018)
Has Leap Therapeutics been receiving favorable news coverage?
News coverage about LPTX stock has trended somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Leap Therapeutics earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Leap Therapeutics' key competitors?
Some companies that are related to Leap Therapeutics include Synlogic (SYBX), Calithera Biosciences (CALA), Proteostasis Therapeutics (PTI), Xenon Pharmaceuticals (XENE), MEI Pharma (MEIP), Chimerix (CMRX), Unum Therapeutics (UMRX), Nature's Sunshine Products (NATR), Bellicum Pharmaceuticals (BLCM), Recro Pharma (REPH), Poxel (PXXLF), Corvus Pharmaceuticals (CRVS), Spring Bank Pharmaceuticals (SBPH), Protagonist Therapeutics (PTGX) and ContraFect (CFRX).
Who are Leap Therapeutics' key executives?
Leap Therapeutics' management team includes the folowing people:
- Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 64)
- Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 49)
- Mr. Augustine J. Lawlor, Chief Operating Officer (Age 62)
- Dr. Cynthia A. Sirard, VP of Clinical Devel.
Who are Leap Therapeutics' major shareholders?
Leap Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (6.26%), Sphera Funds Management LTD. (2.26%), Vanguard Group Inc (1.74%), Vanguard Group Inc. (1.74%), Renaissance Technologies LLC (0.94%) and JPMorgan Chase & Co. (0.10%). View Institutional Ownership Trends for Leap Therapeutics.
Which institutional investors are selling Leap Therapeutics stock?
Which institutional investors are buying Leap Therapeutics stock?
How do I buy shares of Leap Therapeutics?
Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Leap Therapeutics' stock price today?
One share of LPTX stock can currently be purchased for approximately $2.82.
How big of a company is Leap Therapeutics?
Leap Therapeutics has a market capitalization of $47.05 million. The company earns $-29,720,000.00 in net income (profit) each year or ($3.31) on an earnings per share basis. Leap Therapeutics employs 22 workers across the globe.
What is Leap Therapeutics' official website?
How can I contact Leap Therapeutics?
Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.
MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
